We are looking for participants for a hepatitis B vaccination study
Over three percent of the world's population (approx. 260 million people) are chronically infected with the hepatitis B virus (HBV). Worldwide, 880,000 people die every year as a result of HBV infection (including liver cirrhosis and liver cancer). Prophylactic vaccines are available to prevent HBV infection. There is currently no curative treatment for chronically infected people.
The Tropical Institute at the LMU Klinikum München is conducting a Phase I vaccine trial with the therapeutic vaccine candidate TherVacB against hepatitis B in collaboration with the Institute for Infection Research and Vaccine Development Hamburg (Prof. Addo) and Helmholtz Munich (Prof. Protzer). The study contributes to the research of a novel therapeutic approach to cure chronic hepatitis B in the TherVacB project.
TherVacB is a publicly funded academic research project. Further information on the project can be found at www.thervacb.eu and www.dzif.de.
We are looking for healthy women and men between the ages of 18 and 65 for the Phase I study.
The study includes a preliminary examination and 12 outpatient visits over a period of approx. 9 months.
General requirements for participation in the study
- 18-65 years
- in good health
for women: not pregnant or breastfeeding
not vaccinated against Mpox (formerly monkeypox) or hepatitis B
no hepatitis B infection in the past
- no regular intake of medication
- BMI (Body Mass Index): 18.5-32.0 kg/m²
- Body weight: at least 50 kg
In addition to comprehensive information about the study and in-depth medical care, you will receive an expense allowance of € 1,800.00 if you participate fully.
Contact for interested parties
Monday - Thursday:
9a.m. to 2.30 p.m.
Tel: 089 4400-59850
E-Mail:
impfstudien-tropeninstitut@
med.uni-muenchen.de
Please state the keyword "Hepatitis B" in your e-mail or when registering via the online form.
If you are interested, please register using the online form
Please enter the keyword after your surname in the online form (surname: keyword Hepatitis B):
Data Usage Notice
Your personal data will be treated confidentially by us and will only be used to contact you by e-mail, telephone and/or in writing as part of this contact. Your information will be adequately protected against access by third parties and collected, processed and used in accordance with the provisions of the Federal Data Protection Act. The provision of your personal data, in particular your data on your health, is voluntary. If necessary, your request will be forwarded to the responsible departments or persons within the Munich University Hospital (KUM). In this context, there is the possibility that non-medical staff of the clinic may gain knowledge of the information you have disclosed. This information will not be passed on or transmitted to third parties outside the clinic. Your data will be deleted no later than 3 months after your information has been evaluated or forwarded to the responsible office. You can revoke your consent to the earmarked processing and use of the data at any time in writing without giving reasons. Your stored data will then be deleted immediately within the framework of legal regulations. The relevant information about your request will be sent or forwarded to you in unencrypted form at the email address you provided, without providing any information about your health. This poses a risk under data protection law. We will only send requested patient and personal application documents to a reasonable extent by post if you have given your postal address. Please also note our general data protection declaration
Cooperation partner
